Veterinary Medicines

Versican Plus BbPI IN nasal drops, lyophilisate and solvent for suspension for dogs

Authorised
  • Canine parainfluenza virus, strain CPiV-2-Bio 15, Live
  • Bordetella bronchiseptica, strain MSLB 3096, Live
Download as PDF

Product identification

Medicine name:
Versican Plus BbPI IN nasal drops, lyophilisate and solvent for suspension for dogs
Versican Plus BbPi IN Neusdruppels, lyofilisaat en oplosmiddel voor suspensie
Versican Plus BbPi IN Lyophilisat et solvant pour suspension nasale en gouttes
Versican Plus BbPi IN Lyophyllisat und Lösungsmittel zur Herstellung von Nasentropfen, Suspension
Active substance:
  • Canine parainfluenza virus, strain CPiV-2-Bio 15, Live
  • Bordetella bronchiseptica, strain MSLB 3096, Live
Target species:
  • Dog
Route of administration:
  • Nasal use

Product details

Active substance and strength:
  • Canine parainfluenza virus, strain CPiV-2-Bio 15, Live
    3.50
    log10 50% tissue culture infectious dose
    /
    1.00
    Dose
  • Bordetella bronchiseptica, strain MSLB 3096, Live
    8.00
    log10 colony forming unit(s)
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and solvent for oral suspension
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AF01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Belgium
Available in:
  • Belgium
Package description:
  • (ID2): 1 Box with (10 Vial (Glass) with 1 Dose and 10 Vial (Glass) with 0.5 millilitre(s)) (10.0 Dose, 5.0 millilitre(s))
  • (ID1): 1 Box with (5 Vial (Glass) with 1 Dose and 5 Vial (Glass) with 0.5 millilitre(s)) (5.0 Dose, 2.5 millilitre(s))

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Zoetis Belgium
Marketing authorisation date:
Manufacturing sites for batch release:
  • Bioveta a.s.
Responsible authority:
  • Federal Agency For Medicines And Health Products
Authorisation number:
  • BE-V557964
Date of authorisation status change:
Reference member state:
  • Germany
Procedure number:
  • DE/V/0288/001
Concerned member states:
  • Austria
  • Belgium
  • Croatia
  • Cyprus
  • Czechia
  • Estonia
  • France
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Netherlands
  • Poland
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 17/08/2025
Download
French (PDF)
Published on: 17/08/2025
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 17/08/2025
Download
French (PDF)
Published on: 17/08/2025
Download
German (PDF)
Published on: 17/08/2025
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 17/08/2025
Download
French (PDF)
Published on: 17/08/2025
Download
German (PDF)
Published on: 17/08/2025
Download

Combined File of all Documents

English (PDF)
Published on: 14/11/2025
Download

2613944-paren-20251101.pdf

English (PDF)
Published on: 27/11/2025
Download